

Index

Numbers in *italics* refer to *tables* and *figures*.

- ABCC6* gene 19, 138
ABCD1 gene 262, 263
 acropustulosis of infancy 120
activin receptor-like kinase (ALK1) gene 39, 159
ADAMTS2 (procollagen 1 N-proteinase) gene 18
 Addison disease 259–60
 adenoma sebaceum 60, 61
 adrenoleukodystrophy
 neonatal 258
 X-linked *see* X-linked adrenoleukodystrophy (X-ALD)
 adrenomyeloneuropathy (AMN) 258, 259, 263
 albinism
 in Chediak–Higashi syndrome 296
 genetics summarized 17
 ocular 17–18
 oculo-cutaneous 16, 17
 albinism-deafness syndrome (ADFN) 18
ALDH10 gene 273
ALDP 262
ALK1 (activin receptor-like kinase) gene 39, 159
 alkylidihydroxyacetonephosphate synthase (alkyl-DHAP synthase; alkylglyceronephosphate synthase; AGPS) 15, 270, 271
 alleles 6
 Alliance of Genetic Support Groups 25
 allopurinol 195
 5-aminolevulinic acid 85
 Amish hair-brain syndrome 33, 39
 amyloidosis 321
 Anderson–Fabry disease *see* Fabry disease
 aneurysms, in Ehlers–Danlos syndrome 144–5
 angiofibromas, facial 60, 61
 angioid streaks 139, 140, 141
 angiokeratoma corporis diffusum *see* Fabry disease
 angiokeratomas, in fucosidosis 214, 215
 Apert's syndrome 99
 apocrine nevi 89, 91, 97
 argininosuccinic acid lyase (ASAL) 12
 argininosuccinicaciduria 12–13
 arterial dissections, in Ehlers–Danlos syndrome 146–7
 arteriovenous malformations (AVMs)
 brain 32, 36
 hereditary hemorrhagic telangiectasia
 association of pulmonary and cerebral 163–4
 cerebral 161, 162–3
 and migraine 163
 pulmonary 160–1, 162
 screening for 164
 spinal 163
 hereditary neurocutaneous angiomas (cerebral) 166, 167, 169, 170, 171
 arylsulfatase E 271
 aspirin 183–4
 ataxia with ocular apraxia (AOA) 114
 ataxia–telangiectasia (AT) 36, 112–16
 clinical features
 cancer risk 113–14
 cutaneous and scleral 2, 112
 mental capacity 113
 neurological 4, 112–13
 ophthalmological 3, 113
 sinopulmonary infections 113
 tumors 3, 113
 differential diagnosis 114
 genetics 5, 11, 115
 laboratory diagnosis 114–15
 management 115
 pathology 114
 ATFresno 113
ATM gene 11, 36, 115
ATM protein 11, 114, 115
ATOX1 229
ATP7A gene 15, 230–1
ATP7A protein 15, 229
ATP7B protein 229
 auditory brain-stem responses (ABR) 56
 autosomal dominant/recessive disorders *see* genetics of neurocutaneous disorders

- autosomes 6–7
- AVMs *see* arteriovenous malformations (AVMs)
- Bannayan–Riley–Ruvalcaba syndrome *see* Bannayan–Zonana syndrome (BZS)
- Bannayan–Zonana syndrome (BZS) 10, 36, 133, 134
- basal cell carcinomas 77, 78, 79, 84–5
- basal cell nevus syndrome *see* nevoid basal cell carcinoma syndrome (NBCCS)
- basaloid follicular hamartomata 79, 84
- Bazex syndrome 84
- Bean syndrome *see* blue rubber bleb nevus syndrome (BRBNS)
- Becker's nevi 91, 94
- behavioral problems
 - Lesch–Nyhan syndrome 188–9, 195, 196
 - Sturge–Weber syndrome 180
 - tuberous sclerosis complex 63
- beige mouse 298
- betaine therapy 211
- betaine-homocysteine methyltransferase 206, 207
- bile acid synthesis
 - cerebrotendinous xanthomatosis patients 251, 252–3
 - normal 251, 252
- bile alcohols, in cerebrotendinous xanthomatosis 252, 253, 255
- biotin
 - metabolism 200, 201
 - structure and function 200
 - supplementation in multiple carboxylase deficiency 204
- biotinidase 200, 201
- biotinidase deficiency (late onset MCD)
 - clinical features 2, 3, 202, 203
 - diagnosis 203
 - genetics 5, 203–4
 - pathology 203
 - radiographic findings 203
 - treatment 204
 - see also* holocarboxylase synthetase deficiency (early onset MCD)
- birth defects, categories summarized 28
- Blaschko's lines 89, 91, 98, 117, 128
- blue rubber bleb nevus syndrome (BRBNS) 154–8, 170
 - clinical features
 - cerebrovascular 5
 - gastrointestinal 4, 154, 156–7
 - neurological complications 154, 157
 - venous malformations 2, 154, 155, 156, 157
 - tumors 3, 154
 - genetics 5, 11, 157
 - history 154
 - pathology 157
 - treatment 157–8
- bone marrow transplantation
 - Chediak–Higashi syndrome 299
 - Lesch–Nyhan syndrome 196
 - X-linked adrenoleukodystrophy 263
- Bonnet–Deschaume–Blanc syndrome 170
- brachymorphism–onychodysplasia–dysphalangism (BOD) syndrome 316
- C-cell hyperplasia 105, 108
- café-au-lait macules 43, 44, 51
- calcipotriol 101
- calcitonin 105
- calcitonin stimulation tests 106
- calcium intake in pseudoxanthoma elasticum 142
- cancer predisposition in neurocutaneous disorders 35–6
 - see also specific disorders*
- cape nevi 71, 72
- cardiac diseases associated with neurocutaneous disorders 4
 - see also specific disorders*
- carotid-cavernous fistulae 145–6
- carpal tunnel syndrome 323, 325
- cataracts, in cerebrotendinous xanthomatosis 248, 249
- cation pumps 229
- CBS *see* cystathionine β -synthase (CBS)
- CCS 229
- cerebello-trigemino-dermal (CTD) dysplasia 32, 36, 306–12
 - cases reported 306
 - clinical features 2, 3, 4, 306–10
 - genetics 5, 311
 - management 311
 - pathology 310
 - prognosis 311
 - radiographic findings 307, 308, 310
- cerebral cavernous malformations 32, 37
- cerebrotendinous xanthomatosis (CTX) 248–57
 - bile acid synthesis 251, 252–3
 - clinical features 3, 4, 5, 248–9
 - diagnosis 253
 - genetics 5, 13, 254
 - genotype–phenotype correlations 254–5
 - investigations 251
 - management 255–6
 - pathology 253–4
 - radiographic findings 249–51
 - sterol 27-hydroxylase knockout mice 255
 - therapy 255, 256
- cerebrovascular lesions with neurocutaneous disorders 5
 - see also specific disorders*
- ceruloplasmin 229, 230
- CGI-58 gene 19
- chaperones, copper 229
- Charcot joint 280
- Chediak–Higashi syndrome (CHS) 296–300
 - clinical features
 - accelerated phase 298
 - coagulation defects 298
 - cutaneous and ocular 2, 3, 296
 - immunodeficiency 297
 - neurological 4, 297–8
 - recurrent infections 296
 - diagnosis 296
 - prenatal 298–9
 - genetics 5, 14, 298
 - management 299
 - pathology 298
 - prognosis 299
- Chediak–Higashi-like syndrome (CHLS) 14
- chenodeoxycholic acid (CDCA) 248, 253, 255, 256

- CHILD (congenital hemidysplasia with ichthyosiform nevus and limb defects) syndrome 90–1, 94, 98, 99
 cholestanol 248, 252, 253, 255
 chondrodysplasia punctata syndromes 99, 268, 271
 chromosomal disorders 25, 26
CHS1 gene 14, 298
 cleft palate 29
 clinical recognition of neurocutaneous disorders
 disorders summarized 32–3
 general characteristics 31, 33–4
 important findings
 cancer predisposition 35–6
 intracranial 34
 macrocephaly 34
 microcephaly 34
 neurological 34
 skin 31, 34–5
 others 35
 see also congenital anomalies; genetic disorders;
 specific disorders
 club foot 29, 30
 COACH syndrome 32
 cobalamin (vitamin B12) 206
 Cobb syndrome 170, 174
 Cockayne syndrome (CS)
 clinical features 2, 3, 4, 235, 238–40, 241, 243
 complementation groups 235
 genetics 5, 15, 242, 244, 245
 history 236
 neurological findings 241–2
 neuropathology 242
 radiographic findings 241
 see also DNA damage and repair
 codons 7
 Coffin–Lowry syndrome 315
 Coffin–Siris syndrome (CSS) 313–17
 clinical features 2, 4, 313, 314, 315
 cognitive development 316
 differential diagnosis 315–16
 genetics 315
 pathology 313–14
 radiographic findings 313, 315
COL3A1 gene 147
 collagen cross-linking
 in Menkes disease 226, 227
 normal 225–6
 collagen gene mutations, Ehlers–Danlos syndromes 17, 18, 147
 computerized tomography (CT) scans
 cerebral arteriovenous malformations 168, 169
 cerebrotendinous xanthomatosis 249
 Coffin–Siris syndrome 313
 Cowden disease 133
 Dandy–Walker malformation 175
 encephalocraniocutaneous lipomatosis 303, 304
 epidermal nevus syndromes 96
 fucosidosis 216
 giant axonal neuropathy 292
 hypomelanosis of Ito 127
 lipoid proteinosis 320
 medullary thyroid carcinoma 107
 Menkes disease 225
 neurofibromatosis type 2, 52
 pheochromocytomas 107
 Sturge–Weber syndrome 181
 tuberous sclerosis complex (TSC) 64
 congenital anomalies
 causes summarized 29
 classification
 categories summarized 28
 isolated anomalies 29–30
 multiple anomalies 30–1
 sequences 28, 30
 congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome 90–1, 94, 98, 99
 connective tissue pathology in Menkes disease 225–6
 Conradi–Hunermann syndrome 99, 268, 271
 copper
 cellular transport 229
 measurement of intracellular accumulation 231
 normal metabolism 228–9
 therapy 231–2
 toxicity 228
 see also Menkes disease
 Cornelia de Lange syndrome 315
 counseling 25
 Cowden disease (CD) 32, 37, 131–7
 clinical features 3, 4, 131–2
 dermatological 2, 131
 neurological 133
 systemic 133
 genetics 5, 131, 133–4
 history 131
 management 135
 neuropathology 135
 radiographic findings 133
 related disorders
 Bannayan–Zonana syndrome 10, 36, 133, 134
 juvenile polyposis syndrome 133
 Lhermitte–Duclos disease 9, 132–3, 135
 COX17 229
 Crowe's sign 45
 CS (Cockayne syndrome) genes 245
 CTX *see* cerebrotendinous xanthomatosis (CTX)
 cutaneomeningospinal angiomas (Cobb syndrome) 170, 174
 cutaneous hemangiomas–vascular anomaly complex, 2, 3, 5, 172–8
 clinical features 173–5
 course 175
 genetics 5, 177
 management 177
 pathology 175
 radiographic findings
 cerebellar malformations 175
 vascular abnormalities 175–7
 cutaneous lichen amyloidosis 106
 cutaneous neurofibromas 43, 45
CYP27 gene 13, 254, 255
 see also sterol 27 hydroxylase (CYP 27)
 γ -cystathionase 206, 207

- cystathione β -synthase (CBS) 13, 206, 207, 211
 gene mutations 211
 see also homocystinuria due to CBS deficiency
 cytogenetic testing 26
- Dandy-Walker malformation 72–3, 175, 313
 deep nodular neurofibromas 45
 deformations 28, 29, 30
 5-deoxyadenosylcobalamin (AdoCbl) deficiency 206–7
 DeSanctis-Cacchione (XP neurological) syndrome 238, 241,
 242, 243, 245
 developmental field defects 28, 30
 developmental venous abnormalities (DVAs) 166, 168, 169, 170
 dihydroxyacetonephosphate acyltransferase (DHAPAT) 15, 270, 271
 1,25-dihydroxycholecalciferol 101
 dipyrindamole 212
 disruptions 28, 29, 30
 DNA damage and repair 234–6
 DOOR syndrome 316
 dopamine beta-hydroxylase deficiency 230, 231
 Dorfman-Chanarin syndrome 18–19
 DVAs *see* developmental venous abnormalities
 dysmorphology examinations 27–8
 dysplasias 28, 29, 30
 dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos
 disease) 9, 132–3, 135
- eccrine nevi 91, 97
ECM1 (extracellular matrix protein 1) gene 14, 321
 Ehlers-Danlos syndrome (EDS) subtypes 17, 18, 144, 147
 Ehlers-Danlos syndrome (EDS) type IV 144–9
 clinical features 2, 4, 144, 145
 aneurysms 5, 144–5
 arterial dissections 146–7
 carotid-cavernous fistulae 145–6
 diagnosis 144
 genetics 5, 147
 prevalence 144
 Ehlers-Danlos syndrome type IX *see* occipital horn syndrome (OHS)
 elastic fibers
 Menkes disease 227
 normal connective tissue 225–6
 emboli, complicating pulmonary AVMs 162
 encephalocraniocutaneous lipomatosis (ECCL) 32, 37, 301–5
 clinical features
 cerebrovascular 5, 303–4
 cutaneous 2, 302
 ophthalmologic 3, 302
 orthopedic 302
 tumors 3, 302
 diagnostic criteria 303
 genetics 5, 19, 304–5
 management 305
 original descriptions 301
 pathology 304
 prognosis 305
 radiographic findings 303–4
 relationship with Proteus syndrome 19, 301–2
 encephalofacial angiomatosis *see* Sturge-Weber syndrome (SWS)
ENG (endoglin) gene 10, 39, 159
- ependymomas 53, 54
 epidermal nevus syndromes (ENS) 32, 37, 88–104
 clinical features 89
 cutaneous 2, 89–91
 endocrine abnormalities 95
 malignancy 3, 95–6
 neurological 91–3
 ocular 3, 93–4
 skeletal 94–5
 others 95
 definition issues 88
 genetics and mosaicism 5, 19–20, 97–8
 histopathology 96–7
 management 100–1
 pathogenesis
 cutaneous phenotypes 98–9
 extracutaneous phenotypes 99–100
 radiographic findings 96
 subsets 88
 epidermolytic hyperkeratosis 88, 98
 epididymal cystadenomas 66–7
 epistaxis, treatment of 159
ERCC3 (excision repair cross-complementary) gene 244
 erythrokeratoderma with ataxia 32, 37
 erythropoietic protoporphyria 321
 etretinate 84
 eumelanin 16
excision repair cross-complementary (ERCC3) gene 244
 excitotoxicity 210–11
 expressivity 8
extracellular matrix protein 1 (ECM1) gene 14, 321
- Fabry disease 286–90
 clinical features 2, 3, 4, 5, 286, 287
 diagnosis 288
 genetics 5, 15–16, 288
 neurological complications 286–8
 pathology 288
 treatment 288–9
 facial palsy 51
 familial dysautonomia 277–85
 clinical features 3, 4, 277
 cutaneous 280
 gastrointestinal 277–8
 neurological 281
 ophthalmologic 278, 280
 orthopedic 278, 280
 renal 281
 respiratory 278
 vascular 280–1
 summarized 279
 diagnostic criteria 277, 278
 genetics 5, 14, 283
 management 283–4
 pathology 282–3
 prognosis 284
 radiographic findings 281–2
 familial medullary thyroid carcinoma (FMTC) 105, 106, 109
 Fanconi anemia 32
 fatty aldehyde dehydrogenase (FALDH) 273

- FBN1* (*fibrillin-1*) gene 8
 Ferguson-Smith syndrome 83
 fetal akinesia (immobility) sequence 30
 fetal hydantoin syndrome 315
 fetal rhabdomyomas 81
fibrillin-1 (*FBN1*) gene 8
 fibroblast growth factor receptor 2 (FGFR2) 99
 fibrolipomatous hamartomas of nerve 323, 324
 5-fluorouracil 84, 101
 folate supplementation 211
 follicular tumors 90
 founder effect 11
 freckles, skinfold (Crowe's sign) 45
 Friedrich's ataxia 114, 292
 Fryns syndrome 315–16
FUCA1/2 genes 14
 fucose 218
 α -L-fucosidase 14, 218
 fucosidosis 214–21
 biochemistry 218
 clinical features 2, 3, 4, 214
 type 1 (rapid progression) 214–15
 type 2 (chronic) 215–16
 differential diagnosis 219
 genetics 5, 14, 218
 management 219
 pathology 216–18
 pathophysiology 218–19
 prognosis 219
 radiographic findings 216
 fucosyl-gangliosides 218
- α -galactosidase A (GLA)
 deficiency in Fabry disease 15–16, 288
 replacement therapy 288–9
GAN (*giant axonal neuropathy 1*) gene 14, 294
 gastrointestinal abnormalities with neurocutaneous disorders 4
 see also specific disorders
 Gaucher disease 13, 16
GBA (β -glucosidase) gene 13
 gene mutations 7
 see also specific genes
 genetic disorders
 approach to patients 24–5
 counseling 25
 dysmorphology examinations 27–8
 importance in medicine 24
 recognition of inheritance mechanisms 25, 26
 see also congenital anomalies; specific disorders
 genetic testing 25–6
 biochemical/metabolic 26
 cytogenetics 26
 DNA testing 27
 genetics of neurocutaneous disorders 5, 6–23
 background
 expressivity 8
 genetic heterogeneity 8
 inheritance patterns 5, 6–7
 mosaicism 8
 mutation types 7
 penetrance 7–8
 autosomal dominant disorders
 characteristics 8
 examples 9
 genetically heterogeneous 10–11
 single gene mutations 8–10
 unidentified gene mutations 11
 autosomal recessive disorders
 characteristics 11
 examples 12
 genetically heterogeneous 14–15
 single gene mutations 11–14
 genetic heterogeneity and multiple inheritance types 16–19
 mosaicism, disorders due to 19–20
 pedigrees 25, 26
 X-linked disorders
 characteristics 15
 dominant, with genetic heterogeneity 16
 examples 16
 recessive single gene defects 15–16
 see also specific disorders
 genotypes 6
 giant axonal neuropathy (GAN) 291–5
 clinical features 4, 291, 292
 differential diagnosis 291–2
 genetics 14, 294
 pathology 292–4
 prognosis 294
 radiographic findings 292
 treatment 294
 giant lysosomes 297, 298
 gigaxonin 14
 GLA *see* α -galactosidase A (GLA)
 glaucoma, in Sturge-Weber syndrome 181, 184
 gliomas 44, 45–6, 54
 global genome repair (GGR) 236
 β -glucosidase (*GBA*) gene 13
 glutathione 229
 glyceryl trioleate/glyceryl trierucate mixture 263
GNAS1 gene 19
 Gómez-López-Hernández syndrome *see* cerebello-trigemino-dermal (CTD) dysplasia
 Gorlin syndrome *see* nevoid basal cell carcinoma syndrome (NBCCS)
 gout 189, 190
 Griscelli (Chediak-Higashi-like) syndrome 14
 Gröbblad-Strandberg syndrome *see* pseudoxanthoma elasticum (PXE)
- HAH1 229
 hair abnormalities 2
 see also specific disorders
 hamartin 11, 40, 64
 hedgehog signaling pathway 83–4
 hemangioblastomas 67, 68
 hemangiomas *see* cutaneous hemangiomas-vascular anomaly complex
 hereditary hemorrhagic telangiectasia (HHT) 33, 39, 159–65
 clinical features
 cerebrovascular 5, 160, 161, 162–3
 cutaneous 2, 159–60
 epistaxis 159
 gastrointestinal bleeding 4, 161
 hepatic 163

- hereditary hemorrhagic (*Cont.*)
 ophthalmological 3, 159–60
 pulmonary AVMs 160–1
 diagnostic criteria 164
 genetics 5, 10, 159
 history 159
 neurological complications
 cerebral AVMs 161, 162–3
 migraine 163
 secondary to pulmonary AVMs 161, 162
 spinal AVMs 163
 resource for patients/practitioners 164
 screening for AVMs 164
 hereditary hypo/hyperpigmented macules 32, 38
 hereditary neurocutaneous angiomatosis (HNA) 32, 38, 166–71
 clinical features
 cerebral 5, 166–7
 cutaneous 2, 166, 167
 spinal syndromes 167–8
 differential diagnosis
 neurocutaneous vascular hamartomas 170
 phacomatoses 169
 genetics 5, 11, 169
 management 170
 pathology
 cutaneous lesions 168–9
 intracranial lesions 169
 prognosis 170–1
 radiographic findings 168
 hereditary sensory and autonomic neuropathies (HSANs) 283
 hereditary ataxia polyneuritisformis *see*
 Refsum disease
 hexacosanoic acid 262
 HHT *see* hereditary hemorrhagic telangiectasia (HHT)
HHT1/HHT2 genes 159
 Hirschprung disease (HSCR) 107
HLCS (holocarboxylase synthetase) gene 13, 202
 β -HMG-CoA reductase inhibitors 255
 holocarboxylase synthetase 201
 holocarboxylase synthetase deficiency (early onset MCD)
 clinical features 2, 3, 200–1
 diagnosis 201–2
 genetics 5, 13, 202
 radiographic findings 201
 treatment 204
 see also biotinidase deficiency (late onset MCD)
holocarboxylase synthetase (HLCS) gene 13, 202
 holoprosencephaly spectrum 30
 homocysteine neurotoxicity 210
 homocystinuria 13, 206–7
 homocystinuria due to CBS deficiency 206–13
 clinical features
 cardiac 4, 210
 central nervous system 208
 eye 3, 208
 skeletal 208
 skin and hair 2, 209
 variability 209
 vascular 5, 208–9
 summarized 209
 diagnosis 207
 genetics 5, 13, 211
 management 211–12
 pathology 210–11
 radiographic findings 209–10
 HPRT *see* hypoxanthine guanine phosphoribosyl transferase (HPRT)
 Huntington's disease 210
 Hutchinson–Gilford progeria syndrome *see* progeria
 7 α -hydroxylase 251, 252, 253, 255
 3 β -hydroxysteroid dehydrogenase 99
 3 Δ -hydroxysteroid isomerase 99
 hyperparathyroidism 107, 110
 hyperuricemia 189–90
 hypomelanosis of Ito (HI) 2, 32, 37–8, 123–30
 chromosome abnormalities 20, 128
 clinical features
 musculoskeletal 124, 125–6
 neurological 124–5
 ocular 3, 126
 oral 124, 125
 skin and hair 2, 123–4
 tumors 3, 125
 others 126
 differential diagnosis 126
 etiology and genetics 5, 123, 127–8
 management 128–9
 pathology 127
 prevalence 123
 prognosis 126
 radiographic findings 127
 hypophosphatemic vitamin D-resistant rickets 95, 99–100, 101
 hypoxanthine guanine phosphoribosyl transferase (HPRT)
 activity assessment in cultured fibroblasts 191
 catalytic reactions 186, 187
 deficiency variants
 Lesch–Nyhan 190
 neurological 191–2
 partial 190–1
 summarized 191
 gene mutations in Lesch–Nyhan syndrome 16, 186, 194
 ichthyosiform erythroderma 269
 ichthyosis follicularis with atrichia and photophobia (IFAP) 18
 ichthyosis and male hypogonadism 32, 38
 ichthyotic neutral lipid storage disease (INLSD) 18–19
IKBKAP gene 14, 283
 ILVEN *see* inflammatory linear verrucous epidermal nevi (ILVEN)
 incontinentia pigmenti achromians *see* hypomelanosis of Ito (HI)
 incontinentia pigmenti (IP) 32, 38, 117–22
 clinical features
 hair 2,
 neurological 120
 ophthalmological 3, 118–20
 skin 2, 117–18
 others 118
 summarized 118
 differential diagnosis 120–1
 genetics 5, 16, 121
 management 121–2
 pathology 120

- infantile onset MCD *see* biotinidase deficiency (late onset MCD)
- inflammatory linear verrucous epidermal nevi (ILVEN)
 calcipotriol treatment 101
 clinical features 89–90, 91, 94, 99
 histopathology 97
- interferon treatment of hemangiomas 177
- intralesional photocoagulation 177
- involucrin 97
- isotretinoin 84, 245
- isovaleric academia 201
- juvenile polyposis syndrome (JPS) 133
- Kassabach–Merritt syndrome 157
- keratin gene mutations 20, 98–9
- keratinization, copper-dependence of 230
- keratinocytic (verrucous) epidermal nevi 89, 92, 96, 101
- kinky hair syndrome *see* Menkes disease
- Klippel–Trenaunay–Weber syndrome 32, 38, 163, 179
- Krit1* gene 37
- lansoprazole 157
- laser treatment 101, 177, 184
- leptomeningeal melanosis 72
- Lesch–Nyhan syndrome 186–99
 clinical features
 aggression 188–9
 early 187
 megaloblastic anemia 190
 mental retardation 187–8
 resulting from hyperuricemia 189–90
 self-injurious behavior 188, 189
 spasticity 187
 defective enzyme 190
 diagnosis 190
 genetics 5, 16, 186, 194
 heterozygote detection 194–5
 management
 allopurinol 195
 behavior modification 195, 196
 bone marrow transplantation 196
 gene therapy 196
 5-hydroxytryptophan and carbidopa 195
 pathology 193–4
 prenatal diagnosis 195
 prognosis 196
 progress to date 186
 radiographic findings 192–3
- leukotriene B₄ 274
- leuprolide acetate 101
- Lhermitte–Duclos disease (LDD) 9, 132–3, 135
- linear and whorled hypermelanosis 118
- lines of Blaschko *see* Blaschko's lines
- linkage studies 27
- lipoid proteinosis 318–22
 clinical features 2, 3, 318, 319, 320
 differential diagnosis 321
 genetics 5, 14, 321
 management 321
 neurological complications 318–19
 pathology 319–21
 radiographic findings 319, 320
- Lisch nodules 44, 45
- livedo reticularis 209
- localized acquired cutaneous PXE 139
- Lorenzo's oil 263
- lymphangiomyomatosis (LAM) 62
- lyonization 15
- lysyl hydroxylase 18
- lysyl oxidase (LOX) 225, 230
- McCune–Albright syndrome (MAS) 19, 96
- macroductyly–nerve fibrolipoma 323–5
 clinical features 3, 4, 323, 324
 diagnosis 323, 324
 genetics 5
 management 324–5
 pathogenesis 324
 pathology 324
- magnetic resonance imaging (MRI)
 arteriovenous malformations 162–3, 168
 cerebello-trigemino-dermal dysplasia 307, 308, 310
 cerebrotendinous xanthomatosis 249–51
 Cowden disease 133, 134
 epidermal nevus syndromes 96
 fucosidosis 216
 giant axonal neuropathy 292
 hypomelanosis of Ito 127
 lipoid proteinosis 320
 medullary thyroid carcinoma 107
 Menkes disease 225
 neurocutaneous melanosis 74
 neurofibromatosis type 2 53, 56–7
 optic pathway gliomas 44, 46
 pheochromocytomas 107
 Sjögren–Larsson syndrome 273
 Sturge–Weber syndrome 181, 182
 tuberous sclerosis complex 64
 X-linked adrenoleukodystrophy 261
- malformations 28, 29
- malignant melanomas 71, 73, 74
- malignant peripheral nerve sheath tumors (MPNSTs) 46, 54
- mandibuloacral dysplasia 150
- Marfan syndrome 8
- MCD *see* multiple carboxylase deficiency (MCD)
- medullary thyroid carcinoma (MTC) 105–6, 107, 108, 110
- medulloblastoma 80–1
- melanin synthesis 16
- melanocytes 74
- MEN-2 *see* multiple endocrine neoplasia type 2 (MEN-2)
- Mendelian inheritance 25
- meningiomas 51, 53, 54
- Menkes disease 222–33
 carrier identification 231
 clinical features
 cerebrovascular 5, 227
 classical disease 222–3, 224–5
 intermediate phenotypes 224–5
 occipital horn syndrome 223–4
 cutaneous 2, 227

- Menkes disease (*Cont.*)
 diagnosis 231
 genetics 5, 15, 230–1
 incidence 230
 pathology
 arteries 227
 bone and cartilage 227
 connective tissue 225–6
 eyes 228
 lung 227
 neuropathology 227–8
 skin and hair 224–5, 227
 physiopathology
 connective tissue changes 230
 copper homeostasis 229; *see also* copper
 neurological changes 230
 prenatal diagnosis 231
 prognosis 231
 radiographic and other findings 225
 treatment 231–2
- merlin (schwannomin) 10, 55
- Merrick, Joseph 39, 42
- mesenteric cysts 81
- ¹³¹I-metaiodobenzylguanidine (MIBG) scintigraphy 107
- metallochaperones 229
- metallothionein 229
- methionine adenosyltransferase 206, 207
- methionine synthase 206, 207
- methylcobalamin (MeCbl) deficiency 206–7
- methylenetetrahydrofolate reductase (MTHFR) deficiency 206
- metyrosine 110
- ¹³¹I-MIBG scintigraphy 107
- MIDAS syndrome 121
- migraine 163
- moniliform blepharosis 318, 319
- mosaicism 1, 8
 disorders
 encephalocraniocutaneous lipomatosis/Proteus syndrome 19, 304
 epidermal nevus syndromes 19–20, 97–8, 100
 hypomelanosis of Ito 20, 123, 128
 McCune–Albright syndrome 19
 neurofibromatosis type 1 10
 neurofibromatosis type 2 10, 55
 skin pigmentary patterns 123
- mouse models
 Chediak–Higashi syndrome 298
 CYP27 knockouts 255
 hereditary hemorrhagic telangiectasia 159
 X-linked adrenoleukodystrophy 262
- Moya Moya syndrome 46
- multidrug resistance-associated protein 6 (MRP6; ABCG6) 19, 138
- multiple carboxylase deficiency (MCD) 200
see also biotin metabolism; biotinidase deficiency (late onset MCD); holocarboxylase synthetase deficiency (early onset MCD)
- multiple endocrine neoplasia type 2 (MEN-2) 105–11
 clinical features
 C-cell hyperplasia 105
 gastrointestinal symptoms 4, 107
 Hirschprung disease 107
 hyperparathyroidism 107
 medullary thyroid carcinoma 105–6
 multiple somatic features 107
 ophthalmological 3, 107
 pheochromocytomas 106–7
 skin 2, 106
 clinical spectrum 105, 106
 genetic 9, 109
 genetic screening 109–10
 management 110
 pathology 108–9
 radiographic findings 107
- multiple hamartoma syndrome *see* Cowden disease (CD)
- multiple hemangiomas 170
- MYO5A gene 14
- Naegeli syndrome 121
- National Association for PXE (NAPE) 142
- NBCCS *see* nevoid basal cell carcinoma syndrome (NBCCS)
- NEMO gene 16, 121
- neonatal adrenoleukodystrophy (NALD) 258
- neonatal onset MCD *see* holocarboxylase synthetase deficiency (early onset MCD)
- neonatal progeria 151
- nerve fibrolipomas 323, 324
- neurocutaneous angiomas *see* hereditary neurocutaneous angiomas
- neurocutaneous disorders
 clinical features summarized 2–5
 clinical recognition *see* clinical recognition of neurocutaneous disorders
 concept of 1
 genetics *see* genetics of neurocutaneous disorders
 summarized 32–3
- neurocutaneous melanosis (NCM) 33, 38, 71–6
 clinical features
 cutaneous 2, 71–2
 malignancies 3, 71–2, 73
 neurological 72–4
 diagnostic criteria 71
 genetics 5
 management 75
 neuroimaging findings 74
 pathogenesis 74–5
- neuroectodermal melanolysosomal disease 33
- neurofibromas 43, 44, 45, 54
- neurofibromatosis type 1 (NF1) 33, 39, 42–9
 clinical features
 cerebrovascular 5, 46–7
 learning disabilities 47
 Lisch nodules 43, 44
 neurological 4
 ophthalmological 3
 orthopedic 46–7
 pigmentary 2; café-au-lait macules 43, 44; freckling 45
 tumors 3; malignant peripheral nerve sheath tumor 46;
 neurofibromas 43, 45; optic pathway gliomas 44, 45–6;
 plexiform neurofibromas 44, 45; other malignancies 46

- diagnostic criteria 42–3, 44
- diagnostic features 43–4
- genetics 5, 10, 47
- history 42
- neurofibromatosis type 2 (NF2) 33, 39, 50–9
 - clinical features 2, 3, 4, 50–2
 - diagnostic criteria 50, 51
 - future 57
 - genetics 5, 10, 54–6
 - management
 - screening 56–7
 - surgery 57
 - modifying factors 56
 - pathology 54
 - predictive diagnosis 55–6
 - prevalence 54
 - radiographic findings 53
 - separation from NF1 50
 - variant forms 56
- neurofibromin 10, 47
- neurofibromin* (NF1) gene 10, 39, 47, 304–5
- neurofilaments 291, 293–4
- neuromelanin 74
- nevroid basal cell carcinoma syndrome (NBCCS) 32, 36, 77–87
 - clinical features
 - brain tumors 80–1
 - cardiac fibromas 81
 - craniofacial 77
 - cutaneous 2, 77, 78–80
 - fetal rhabdomyomas 3, 81
 - frequencies of 78
 - hypogonadism 80
 - mesenteric cysts 81
 - musculoskeletal 80, 82–3
 - ocular 77
 - odontogenic keratocysts 80, 82
 - ovarian tumors 81, 82, 83
 - renal 80
 - tumors, miscellaneous 3, 81
 - diagnostic criteria 78
 - differential diagnosis 84
 - genetics 5, 10, 83–4
 - history 77
 - management 84–5
 - prevalence 77
 - radiographic findings 81–3
- nevus comedonicus
 - clinical features 90, 94
 - gene mutation 98, 99
 - histopathology 97
 - mosaicism 99
- nevus sebaceus (NS) of Jadassohn
 - clinical features 37, 89, 90, 92, 95
 - gene mutation 98, 99
 - histopathology 96–7
- nevus syringocystadenoma papilliferum 89, 91, 97
- NF1 gene 10, 39, 47, 304–5
- NF2 gene 10, 54–6
- Nijmegen breakage syndrome (NBS) 33, 114
- nodular plexiform neurofibromas 45
- Norrie syndrome 121
- nucleotide excision repair 235–6
- nucleotide excision repair (NER)-related syndromes 234
 - clinical features summarized 235
 - complementation groups 235
 - genetic classification 235, 242–4
 - history 236–7
 - see also* DNA damage and repair; *specific syndromes*
- occipital horn syndrome (OHS) 147
 - clinical features 223–4
 - radiographic findings 225
- octreotide 157
- ocular albinism 17–18
- oculo-cutaneous albinism 16, 17
- odontogenic keratocysts 80, 82, 84
- omeprazole 157
- Online Mendelian Inheritance in Man 24
- ophthalmic abnormalities in neurocutaneous disorders 3
 - see also specific disorders*
- optic pathway gliomas 44, 45–6
- oral retinoids 84
- organoid nevi 89, 96
- Osler–Weber–Rendu syndrome *see* hereditary hemorrhagic telangiectasia (HHT)
- ovarian tumors 81, 82, 83
- palmar pits 79–80
- pancreatic tumors 66
- paradominant inheritance 98
- Parkes–Weber syndrome 163
- Pascual–Castroviejo syndrome *see* cutaneous hemangiomas–vascular anomaly complex
- PATCHED (PTCH) genes 10, 36, 83, 99
- penetrance 7–8
- peptidyl alpha-amidating enzyme 230
- peripheral neuropathy in neurocutaneous disorders 4
 - see also specific disorders*
- periumbilical PXE 139
- peroxisomal disorders 266
 - see also specific disorders*
- peroxisomal targeting sequences (PTS) 15, 266, 270
- peroxisomes 266
- pervasive developmental disorder (PDD) 316
- PEX7 gene 15, 270
- PHACE syndrome *see* cutaneous hemangiomas–vascular anomaly complex
- phacomatoses (term) 1
- phacomatosis pigmentokeratolica 91, 93, 94
- phenotypes 6
- phenoxybenzamine 110
- phenylketonuria 26
- pheochromocytomas
 - multiple endocrine neoplasia type 2
 - clinical features 106–7
 - imaging 107
 - pathology 108–9
 - preoperative preparation 110
 - screening for 110
- neurofibromatosis type 1 46
- von Hippel–Lindau disease 66

- pheomelanin 16
PHEX gene 100
 photocoagulation 177
 photodermatoses 237
 photodynamic therapy (PDT) 84–5, 142
 photophrin II 85
PHYH gene 268
 phytanic acid 268, 271
 phytanoyl-CoA hydroxylase 268
 pigmented hairy epidermal (Becker's) nevi 91, 94
pink protein gene (*P* gene) 17
 plantar pits 79–80
 plasmalogens 270, 271
 plexiform neurofibromas 44, 45
 port-wine nevi 179, 180, 181
 positron emission tomography (PET), Sturge–Weber syndrome 181–2
 Potter sequence 30
 pravastatin 255
procollagen 1 N-proteinase (ADAMTS2) gene 18
 progeria 150–3
 clinical features 2, 4, 5, 150, 151
 differential diagnosis 5, 150–1
 genetics 151–2
 management 152
 pathogenesis 151
 progeroid syndrome 151
 propionic academia 201
 Proteus syndrome 33
 clinical features 39, 91, 94, 95
 genetics 19, 39, 98, 99
 relationship with encephalocraniocutaneous lipomatosis 19, 301–2
 pseudoxanthoma elasticum (PXE) 138–43
 clinical features
 cardiovascular 4, 139–40
 cerebrovascular 5, 140
 cutaneous 2, 138–9
 gastrointestinal hemorrhage 4, 140
 retinal 3, 139, 140
 diagnosis 141
 genetics 5, 19, 138
 history 138
 management 141–2
 pregnancy 140
 prevalence 138
 support groups 142
PTCH (PATCHED) genes 10, 36, 83, 99
PTEN gene
 identification 133–4
 mutations 134
 Bannayan–Zonana syndrome 10, 36, 133, 134
 Cowden disease 9–10, 37, 131, 134
 juvenile polyposis syndrome 133
 Lhermitte–Duclos disease 9, 133
 malignancies 134
 Proteus syndrome 19
 product 134
 PTS-1/PTS-2 (peroxisomal targeting sequences) 15, 266, 270
 ptychotropism 91
 puberty, precocious 95, 101, 126
 PXE *see* pseudoxanthoma elasticum (PXE)
 pyridoxine therapy 211

RAB27A gene 14
 Rasmussen syndrome 84
 receptor tyrosine kinases 109
RECQL2 gene 12
 Refsum disease
 clinical features 2, 3, 4, 266–7
 diagnosis 268
 genetics 5, 268
 management 268
 pathology 267–8
 Rendu–Osler–Weber syndrome *see* hereditary hemorrhagic telangiectasia (HHT)
RET gene mutations 9, 109
 RET protein 9, 109
 retinitis pigmentosa 266, 267
 rhizomelic chondrodysplasia punctata (RCDP) 268
 clinical features
 cataracts 3, 269
 cutaneous 2, 269
 neurological 269–70
 skeletal 268–9
 others 4
 diagnosis 271
 differential diagnosis 271–2
 genetics 5, 15, 270–1
 rhombencephalosynapsis (RES) 306, 310
 Richner–Hanhart syndrome (RHS) 19
 Riley–Day syndrome *see* familial dysautonomia
 Rombo syndrome 84
 Rud syndrome 32, 38
 rufous oculocutaneous albinism (ROCA) 17
 Ruvalcaba–Myhre–Smith syndrome 10
 Ruvalcaba–Riley–Smith syndrome *see* Bannayan–Zonana syndrome

 schwannomas 54
 see also vestibular schwannomas
 schwannomin (merlin) 10, 55
 scleral telangiectasias 113
 self-injury 188, 189
 Senior syndrome 316
 sequences 28, 30
 L-serine hydro-lyase *see* cystathione β -synthase (CBS)
 sex chromosomes 7
 shagreen patch 60, 61
 simvastatin 255, 256
 single photon emission computed tomography (SPECT), Sturge–Weber syndrome 181–2
 Sipple's syndrome *see* multiple endocrine neoplasia type 2 (MEN-2)
 Sjögren–Larsson syndrome (SLS)
 clinical features 2, 3, 272–3
 diagnosis 273
 genetics 5, 273
 management 273–4
 pathology 273
 radiographic findings 273

- skin lesions
 types 2
 see also specific disorders
 spastic paraplegia with pigmentary abnormalities 33
 sphingolipids 218
 spinal xanthomatosis 249
 steroid treatment of hemangiomas 177
 sterol 27 hydroxylase (CYP 27)
 CYP27 gene 13, 254, 255
 deficiency in CTX 248, 251, 252–3
 knockout mice 255
 in normal bile acid synthesis 251, 252
 stroke 162, 287, 288
 Sturge–Weber syndrome (SWS) 32, 38, 179–85
 clinical features
 cerebrovascular 5, 181, 182–3
 cutaneous 2, 179, 180
 neurological 179–81
 ophthalmologic 3, 181
 genetics 5
 history 179
 pathology 182
 prognosis 184
 radiographic findings 181–2
 treatment
 aspirin 183–4
 glaucoma management 184
 laser 184
 seizure control 182
 surgery 182–3
 subcutaneous neurofibromas 45
 subependymal giant cell astrocytomas (SEGAs) 63
 sulfite oxidase 206, 207
 sulfur amino acid metabolism 206, 207
 superoxide dismutases 230
 syndrome of inappropriate anti-diuretic hormone (SIADH)
 95
 syndromes 28, 30

 TAT (tyrosine aminotransferase) gene 19
 TBL1 (transducin beta-like 1) gene 18
 telangiectasias 112, 113, 159–60, 161
 telomeres 151
 tendon xanthomata 248, 249, 250, 251
 teratogenic syndromes 29
 tetracosanoic acid 262
 thalidomide 177
 thyroidectomy in MEN-2 110
 TIE2 gene 11
 tophaceous gout 189
 transcription-coupled repair (TCR) 236
 transducin beta-like 1 (TBL1) gene 18
 transient ischemic attacks (TIAs) 162, 287
 tretinoin cream 84, 101
 trichorrhexis nodosa syndrome 33, 39
 trichothiodystrophy (TTD)
 clinical features 2, 3, 235, 240
 complementation groups 235
 genetics 5, 15, 242, 244, 245
 history 236
 radiographic findings 242

 see also DNA damage and repair
 TSC1/TSC2 genes 10–11, 64
 tuberin 11, 40, 64
 tuberous sclerosis complex (TSC) 33, 39–40, 60–5
 clinical features
 cardiac 4, 60, 62
 cutaneous 2, 60, 61
 neurological 63
 pulmonary 62
 renal 62
 retinal 3, 60, 62
 tumors 3
 other 4
 diagnostic criteria 61
 genetics 5, 10–11, 64
 management 64–5
 prevalence 60
 radiographic findings 64
 tumors associated with neurocutaneous disorders 3
 see also specific disorders
 tyrosinase (TYR) 16, 17, 209
 tyrosine aminotransferase (TAT) gene 19
 tyrosine hydroxylase 282
 tyrosinemia type II 19

 ungual fibromas 60
 Urbach–Wiethe syndrome *see* lipoid proteinosis
 uric acid, in Lesch–Nyhan syndrome 186, 189–90
 UV exposure
 and NBCCS 78, 83
 and xeroderma pigmentosum 237, 238, 242–3

 VATER association 30
 verrucous (keratinocytic) epidermal nevi 89, 92, 96, 101
 very long chain fatty acids (VLCFAs) 262
 vestibular schwannomas 51, 52, 53, 54, 56
 VHL disease *see* von Hippel–Lindau (VHL) disease
 VHL gene 8–9, 40, 69
 VHL protein 8
 vitamin B6 (pyridoxine) 211
 vitamin B12 (cobalamin) 206
 vitamin D3 (calcipotriol) 101
 VLCFA-CoA synthetase (VLCS) 262
 VLCFAs (very long chain fatty acids) 262
 VMCM1 gene 11
 vomiting crises 278, 283
 von Hippel–Lindau (VHL) disease 33, 40, 66–70
 clinical features
 endolymphatic sac lesions 3, 69
 epididymal cystadenomas 66–7
 hemangioblastomas 3, 67, 68
 pancreatic lesions 3, 66
 pheochromocytomas 3, 66
 renal lesions 3, 66
 retinal angiomas 3, 67, 68
 genetics 5, 8–9, 40, 69
 prevalence 66
 surveillance protocol 69
 treatment 69
 von Recklinghausen disease *see* neurofibromatosis type 1 (NF1)

- warfarin embryopathy 271
 Werner's syndrome
 clinical features 150
 genetics 11–12, 152
 telomeres 151
 Wiedemann–Rautenstrauch syndrome 151
 Wilson disease 229
 woolly hair nevi 91
 Wyburn–Mason syndrome 170
- X-ALD (ABCD1) gene* 262, 263
 X-inactivation 128
 X-irradiation of NBCCS fibroblasts 83
 X-linked adrenoleukodystrophy (X-ALD) 258–65
 clinical features
 adrenal insufficiency 258–60
 cutaneous 2, 260–1
 neurological 258
 phenotypes 259
 genetics 5, 15, 262–3
 management 263
 pathology 262
 pathophysiology 262
 radiographic findings 261
 X-linked chondrodysplasia punctata 271
 X-linked cutis laxa *see* occipital horn syndrome (OHS)
 X-linked hypophosphatemia 100
- X-linked ichthyosis (IFAP syndrome) 18
 X-linked inheritance *see* genetics of neurocutaneous disorders
 xeroderma pigmentosum (XP) 234–47
 clinical features
 cutaneous 2, 237–8
 neurological (DeSanctis–Cacchione syndrome) 238
 ophthalmological 3, 238
 others 238
 summarized 235
 tumors 3
 epidemiology 237
 genetic classification 3, 235, 242–4
 genetic defects 15, 244–5
 history 236–7
 neurological investigations 241
 neuropathology 242
 radiographic findings 241, 242
 treatment 245
 see also DNA damage and repair
XIST gene 128
XP genes 244–5
- Zellweger syndrome 266, 268
 zileuton 274
 Zimmerman, Carol E. *v*